A practical reference on epithalamin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-20 and is reviewed periodically as new material appears.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Linear tetrapeptide | Four residues joined by three peptide bonds |
| Sequence | Ala-Glu-Asp-Gly | Commonly abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free acid form |
| Monoisotopic mass | Approximately 390 Da | Matches values reported from mass spectrometry |
| Net charge near neutral pH | Negative | Contributed by glutamate and aspartate side chains |
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
== Metabolism == A cytochrome P450 enzyme is proposed to metabolize diethyl ether. Diethyl ether inhibits alcohol dehydrogenase, and thus slows the metabolism of ethanol. It also inhibits metabolism of other drugs requiring oxidative metabolism. For example, diazepam requires hepatic oxidization whereas its oxidized metabolite oxazepam does not.
In this model the racemic state is unstable in the sense that the slightest enantiomeric excess will be amplified to a completely homochiral state. This can be shown by computing the reaction rates from the law of mass action:
These grafts were synthesized as a graft copolymer of microfibrillar type I collagen and a glycosaminoglycan, chondroitin-6-sulfate, fabricated into porous sheets by freeze-drying, and then cross-linked by dehydrothermal treatment. Control of the structural features of the collagen scaffold (average pore size, degradation rate and surface chemistry) was eventually found to be a critical prerequisite for its unusual biological activity. In 1981 Burke and Yannas proved that their artificial skin worked on patients with 50 to 90 percent burns, vastly improving the chances of recovery and improved quality of life. John F. Burke also claimed, in 1981, "[The Artificial skin] is soft and pliable, not stiff and hard, unlike other substances used to cover burned-off skin." Several patents were granted to MIT for the creation of collagen-based grafts that can induce dermis regeneration. U.S. Patent 4,418,691 (December 6, 1983) was cited by the National Inventors Hall of Fame as the key patent describing the invention of a process for regenerated skin (Inductees Natl. Inventors Hall of Fame, 2015). These patents were later translated into a commercial product by Integra LifeSciences Corp., a company founded in 1989. Integra Dermal Regeneration Template received FDA approval in 1996, and the FDA listed it as a "Significant Medical Device Breakthrough" in the same year.
Sources: en.wikipedia.org
All these measures, according to the revisionist perspective, would have been allowed by San Martín, knowing that the loss of a large Peruvian capital would benefit the interests of the United Provinces of the Río de la Plata so that it could project as the industrial leader of the South American continent, to the detriment of the Peruvians, since such a compulsive movement against the Hispanic social groups (who were leaders who organized, maintained and dynamized the productive bases that made the bases of the national economy work) did not take place in Chile and Argentina; thus evidencing that primarily the rivalries present in the regional groups of economic power in Latin America, for which both Chileans and Argentines (whose states financed the liberating expedition with the contributions of their bourgeoisies) had feelings and interests contrary to their regional equivalents in Peru (including the Inca nobility for their royalist tendencies), rather than emanating an idealized Spanish-American fraternity against imperialism.
=== Specific risks/complications === Infection: About 0.9-2.5% of patients who undergo Mohs surgery will develop an infection. This is the most frequently documented adverse event with higher rates in patients who are immunosuppressed. To reduce this risk, antiseptics and antibiotics may be used, but the absolute benefit is modest. Impaired wound healing: Dehiscence (partial reopening of the wound) and necrosis (death of healthy tissue) rates are approximately 1-2%. Risk factors include larger excisions, flap/graft use, and immunosuppressed patients. Complication rates decrease when the wound heals with primary closure (using stitches after surgery) or secondary intention (the wound is left open to heal naturally). Hematoma formation and bleeding: This is most commonly seen in patients on antiplatelet or anticoagulant therapy and occurs in 0.9-1.5% of cases. Despite this, patients are not routinely asked to stop these medications, as most experience no complications, and withdrawal is generally not justified. Scarring: 5-7% of cases, especially larger tumors and complex repairs, result in hypertrophic scarring. Less commonly seen are postoperative swelling, rash, and disturbance of skin sensation. Pain is generally mild. Overall, Mohs surgery is generally safe, with risks/complications being minor and manageable.
December 2–3, 1989 – Malta Summit between Bush and Gorbachev, who said, "I assured the President of the United States that I will never start a hot war against the USA". December 10, 1989 – Czechoslovak President Gustáv Husák's resignation amounted to the fall of the Communist regime in Czechoslovakia, leaving Ceaușescu's Romania as the only remaining hard-line Communist regime in the Warsaw Pact. December 25, 1989 – Execution of Nicolae Ceauşescu during the Romanian Revolution against Communist Party rule. December 29, 1989 – Václav Havel assumes the presidency of Czechoslovakia at the conclusion of Velvet Revolution. December 30, 1989 – The Securitate, the secret police of Romania, is dissolved.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.
The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.
The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.